Yahoo
NasdaqGS - Delayed Quote USD

uniQure N.V. (QURE)

44.50 -0.36 (-0.80%)
At close: September 4 at 4:00:00 PM EDT
44.50 0.00 (0.00%)
After hours: September 4 at 7:30:02 PM EDT
Trade QURE on Coinbase
Chart Range Bar
Loading chart for QURE

What's happening with QURE?

43m ago
Powered by Yahoo Scout

uniQure (QURE) has filed a Biologics License Application for its Huntington’s gene therapy, AMT-130, amidst concerns over high valuation metrics. The stock has surged significantly this year but faces risks related to clinical progress and regulatory approvals.

Powered by Yahoo Scout
  • Previous Close 44.86
  • Open 44.91
  • Bid 32.04 x 200
  • Ask 56.74 x 200
  • Day's Range 43.90 - 45.12
  • 52 Week Range 8.73 - 71.50
  • Volume 991,339
  • Avg. Volume 1,847,574
  • Market Cap (intraday) 3.087B
  • Beta (5Y Monthly) 0.94
  • PE Ratio (TTM) --
  • EPS (TTM) -4.06
  • Earnings Date Nov 9, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 69.73

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

www.uniqure.com

221

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

QURE
85.96%
S&P 500 (^GSPC)
12.75%

1-Year Return

QURE
150.99%
S&P 500 (^GSPC)
18.71%

3-Year Return

QURE
410.32%
S&P 500 (^GSPC)
70.93%

5-Year Return

QURE
43.04%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 5.84M
Earnings -81.06M
Profit Margin -1,387.76%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-80M
-60M
-40M
-20M
0
-2000.0%
-1500.0%
-1000.0%

Analyst Insights

View More

Top Analyst

HC Wainwright & Co.
64/100
Latest Rating
Buy

Analyst Price Targets

46.97
69.73 Average
44.50 Current
95.13 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 7/30/2026
Analyst Wells Fargo
Rating Action Maintains
Rating Overweight
Price Action Raises
Price Target 60 -> 75

Statistics

View More

Valuation Measures

Annual
As of 9/2/2026
  • Market Cap

    3.20B

  • Enterprise Value

    2.46B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    160.16

  • Price/Book (mrq)

    10.24

  • Enterprise Value/Revenue

    137.77

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -15.72%

  • Return on Equity (ttm)

    -157.61%

  • Revenue (ttm)

    18.67M

  • Net Income Avi to Common (ttm)

    -252.21M

  • Diluted EPS (ttm)

    -4.06

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    810.33M

  • Total Debt/Equity (mrq)

    170.40%

  • Levered Free Cash Flow (ttm)

    -77.58M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

44.50 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports

View More
  • Lowering target price to $8.00

    UNIQURE NV has an Investment Rating of HOLD; a target price of $8.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of Low.

    Rating
    Price Target
  • What does Argus have to say about QURE?

    UNIQURE NV has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.

    Rating
    Price Target
  • What does Argus have to say about QURE?

    UNIQURE NV has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Low; and a Value Subrating of High.

    Rating
    Price Target
  • Lowering target price to $9.00

    UNIQURE NV has an Investment Rating of HOLD; a target price of $9.000000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Price Target

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: